Just out @NEJM
New data for J&J vaccine:
—High titers of neutralizing antibody to Delta variant, improvement in these levels seen over time
—The antibody and T cell response was durable for at lest 8 months nejm.org/doi/full/10.10…
We needed some good news for this vaccine. This is it.
No sign a booster vs Delta is necessary (study is limited by small number of participants) @FT by @nikasgari
A new lab study preprint compares the 2-dose mRNA vaccines with 1-dose J&J for neutralizing antibodies vs Delta biorxiv.org/content/10.110…
These new data are not contradictory; the @NEJM report did not compare vs mRNA vaccines. nytimes.com/2021/07/20/hea… The headline "ineffective" below is misleading: the neutralizing antibodies w/ J&J were above threshold for concern (dotted line) & there's also the T cell response
• • •
Missing some Tweet in this thread? You can try to
force a refresh
The "D" in Delta stands for a detour in genomic mutations.
Instead of the prior major variants which had N501Y, and E484K for Beta and Gamma, this one took a different path in its spike RBD and other key spots (sequences at @scrippsresearch's outbreak.info) /1
You can see (Delta, in orange) the marked differences from the other variants in multiple locations: receptor binding domain (RBD), N-terminal domain (NTD) and in S2 of the spike protein /2
graphic from @atelentia@Naturenature.com/articles/s4158…
Just published @Nature
Delta variant protection by mRNA and AZ vaccines requires 2-doses, little neutralizing antibody (nAb) with 1-dose, and insufficient nAb with prior covid nature.com/articles/s4158…
A couple of other points from the paper
The mutations unique to Delta (including other B.1.617 lineages, Alpha, Beta, Gamma) include T478K and other regions outside of RBD, highlighted
The large size of fused cells with Delta cf other variants
The @US_FDA's overdue full approval of mRNA vaccines is holding us back from getting millions of more people protected, at a time of urgent need, with the Delta variant on the rise. My guest essay @nytopinionnytimes.com/2021/07/01/opi… w/ thanks for editing @jopearl
I start off w/ the paradox of FDA's accelerated approval of the Alzheimer's drug despite a 10-0 vote against it by their Advisory Committee, 2 clinical trials that did not show clinical benefit, and for any person w/Alzheimer's even though the trials were for early disease, MCI
Then a brief review of the exceptionally large, completed clinical trials and real world evidence for these vaccines—the 1st ever new vaccines to get Emergency Use Authorization (EUA)—now given to hundreds of millions of people /3
This likely represents the Delta variant inflection point for the US, as cases start to increase in several states (log plot to show trend). Let's hope the rise is limited and without much in the way of hospitalizations and deaths.
A lot more people vaccinated would sure help
Mississippi, the least vaccinated state, starts to show an increase in cases. Had dropped to 3.5/100,000 and now back up to 6/100K. Delta is now approaching dominance there; sequencing is limited.
Sequencing data from Mississippi. There's plenty of Delta (B.1.617.2) there now, but confidence intervals are wide outbreak.info
The US is now over 30% Delta variant for new cases. So how could the 7-day average still be heading down, now at 3.2/100,000? Here compared w/UK trajectory, >93% Delta
There's no question that of the new cases in the US, many are Delta, but sequencing is minimal. The 30%+ is based on a limited sample (wide 95% CI) compared with the UK. Look at the numbers at bottom of US, UK graphs outbreak.info
The 30% Delta is very unevenly distributed. Missouri is >60% and is the hotspot of the US for new cases. Neighboring states Arkansas and Oklahoma are also heating up and have high Delta frequency.